Biography
Dissertation Title: Targeting receptor tyrosine kinases in leukemia: from identification of new targets to overcoming mechanisms of resistance
Research Interests: Intrinsic and extrinsic mechanisms of drug resistance in the setting of acute myeloid leukemia
Education and training
-
- B.A., 2011, University of California, Berkeley
- Ph.D., 2021, Oregon Health & Science University
Memberships and associations:
- American Physician-Scientist Association
- American Association for Cancer Research
Honors and awards
- Paul & Daisy Soros Fellowship Award, 2019
- NCI F30 National Research Service Award (NRSA), 2019
- ARCS Foundation Scholar, 2018
Publications
Selected publications
- Joshi SK, Davare MA, Druker BJ, Tognon CE. Revisiting NTRKs as an emerging oncogene in hematological malignancies. Leukemia. 2019 Nov;33(11):2563-2574. doi: 10.1038/s41375-019-0576-8. Epub 2019 Sep 24. PMID: 31551508; PMCID: PMC7410820.
- Nechiporuk T, Kurtz SE, Nikolova O, Liu T, Jones CL, D'Alessandro A, Culp-Hill R, d'Almeida A, Joshi SK, Rosenberg M, Tognon CE, Danilov AV, Druker BJ, Chang BH, McWeeney SK, Tyner JW. The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells. Cancer Discov. 2019 Jul;9(7):910-925. doi: 10.1158/2159-8290.CD-19-0125. Epub 2019 May 2. PMID: 31048320; PMCID: PMC6606338.
- Joshi SK, Qian K, Bisson WH, Watanabe-Smith K, Huang A, Bottomly D, Traer E, Tyner JW, McWeeney SK, Davare MA, Druker BJ, Tognon CE. Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms. Blood. 2020 Jun 11;135(24):2159-2170. doi: 10.1182/blood.2019003691. PMID: 32315394; PMCID: PMC7290093.
- Joshi SK, Keck JM, Eide CA, Bottomly D, Traer E, Tyner JW, McWeeney SK, Tognon CE, Druker BJ. ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia. Leukemia. 2020 Oct;34(10):2798-2804. doi: 10.1038/s41375-020-0844-7. Epub 2020 May 4. PMID: 32366937; PMCID: PMC7515826.
- Joshi SK, Sharzehi S, Pittsenbarger J, Bottomly D, Tognon CE, McWeeney SK, Druker BJ, Traer E. A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance. Am J Hematol. 2021 Jul 1;96(7):E226-E229. doi: 10.1002/ajh.26174. Epub 2021 Apr 13. PMID: 33780043; PMCID: PMC8262663.
- Joshi SK, Nechiporuk T, Bottomly D, Piehowski PD, Reisz JA, Pittsenbarger J, Kaempf A, Gosline SJC, Wang YT, Hansen JR, Gritsenko MA, Hutchinson C, Weitz KK, Moon J, Cendali F, Fillmore TL, Tsai CF, Schepmoes AA, Shi T, Arshad OA, McDermott JE, Babur O, Watanabe-Smith K, Demir E, D'Alessandro A, Liu T, Tognon CE, The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance. Cancer Cell. 2021 Jun 23:
Publications
-
{{ pub.journalAssociation.journal.name.text[0].value }}